The Ministry of Health and Family welfare on 3rd July 2020 has released an updated clinical management protocol for managing COVID-19 cases in which it has revised the dosage of the antiviral drug-remdesivir, being administered to hospitalized COVID-19 patients from the earlier six-days to five-day treatment course.
Under the revised protocol, the drug remdesivir is allowed under emergency use authorization and may be used in patients with moderate disease. The loading dose of 200 mg (shot) on day 1, will now be followed by 100 mg (shot) daily for 4 days (total 5 days). Earlier, the follow-up dose was for 5 days.
Further, the drug cannot be administered to a pregnant or lactating mother and children below the age of 12 years. Also, the drug is not recommended to a patient with severe renal impairment and a high level of liver enzymes.
Click here to read the notification.
